Clinical trials: Hormone Replacement Therapy
Hypercalciuria, Hypercalciuria, Familial Idiopathic
The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement…
- Conditions
- Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
- Trial name
- NCT01928082
- Testing
- Transdermal estradiol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Primary Immunodeficiency Disease
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
- Trial name
- NCT02810444
- Testing
- IgG Next Generation (BT595)
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 81 people
- Sponsor
- Biotest
Tobacco Smoking
Mindfulness Based Smoking Cessation Among Cancer Survivors
This study will examine the effect of a mindfulness-based smoking cessation program among cancer survivors.
- Trial name
- NCT04038255
- Testing
- Nicoderm C-Q Transdermal Product, Orientation session, Craving-to-Quit app
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Miami
Thyroid Diseases
Thyroid and Glucose and Energy Metabolism
This study will examine how two thyroid preparations-levothyroxine (T4) and liothyronine (T3)-affect fat and cholesterol metabolism, blood sugar regulation, and thyrotropin secretion in patients who have had their thyroid gland…
- Trial name
- NCT00106119
- Testing
- Liothyronine and Levothyroxine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
- Conditions
- End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy
- Trial name
- TRANSFORM (NCT01950819)
- Testing
- Induction therapy, Corticosteroids, EVR+rCNI
- Where
- 184 sites in United States, Argentina and 40 more
- Volunteers
- 2,037 people
- Sponsor
- Novartis Pharmaceuticals
SMA - Spinal Muscular Atrophy, Gene Therapy
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
- Trial name
- STR1VE (NCT03306277)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 16 sites in United States
- Volunteers
- 22 people
- Sponsor
- Novartis Gene Therapies
Chronic Kidney Disease
Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)
The EPOCH-RRT study seeks to fill knowledge gaps by gaining more understanding of chronic kidney disease (CKD) patients' priorities; assessing the comparative benefits of hemodialysis (HD) versus peritoneal dialysis (PD), with…
- Trial name
- EPOCH-RRT (NCT01952600)
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Arbor Research Collaborative for Health
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Tobacco Dependence
Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab
The purpose of this study is to assess the bioequivalence between two new oral nicotine replacement therapy products and Nicorette® microtab.
- Trial name
- NCT01238640
- Testing
- Code STD, Code STE, Nicorette Microtab
- Where
- Sweden
- Volunteers
- 84 people
- Sponsor
- McNeil AB
Smoking Cessation
A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline
California Smokers' Helpline will conduct a randomized trial to evaluate 3 strategies of services and/or incentives on smoking cessation rates. This project has the following specific aims: 1.
- Trial name
- NCT01502306
- Testing
- Telephone counseling, Nicotine patches, Incentive
- Where
- United States
- Volunteers
- 3,816 people
- Sponsor
- University of California, San Diego
Anemia
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis.
- Trial name
- NCT00048048
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Alcohol Drinking
Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy
This study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.
- Trial name
- NCT00699556
- Testing
- 21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Yale University
Primary Immune Deficiency
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
The objective of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics of a subcutaneous immune globulin (SCIG; IgPro20) in subjects with primary immunodeficiency (PID).
- Trial name
- NCT01199705
- Testing
- Immune Globulin Subcutaneous (Human) (SCIG)
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- CSL Behring
Smoking Cessation
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
Varenicline is considered to be a first-line tobacco cessation treatment. Previous studies have evaluated the impact of the combination of varenicline and nicotine patches (versus varenicline alone) on smoking cessation, though…
- Trial name
- NCT03722966
- Testing
- Varenicline, Oral Nicotine Replacement Therapy (NRT), Medication Reminders
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Smoking Cessation
Progesterone Augmentation of Nicotine Replacement Therapy Study
This will be a double-blind, placebo-controlled, pilot, randomized clinical trial. A total of 50 women who smoke and have regular menstrual cycles will be randomized to either progesterone (200 mgs BID) + Transdermal Nicotine…
- Trial name
- PANS (NCT02685072)
- Testing
- Progesterone (200 mgs BID)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Yale University
Hypothyroidism, Thyroid Disease
A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
This study will evaluate the safe and effective dose conversion from levothyroxine (synthetic T4) therapy to Armour Thyroid therapy in participants who are on a stable dose of levothyroxine and have thyroid stimulating hormone…
- Conditions
- Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland
- Trial name
- NCT04124705
- Testing
- Armour® Thyroid, Levothyroxine
- Where
- 28 sites in United States
- Volunteers
- 284 people
- Sponsor
- Allergan
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
A pilot study to assess the effects of six months of letrozole on breast tissue risk markers in postmenopausal women on hormone replacement therapy at high risk of developing breast cancer.
- Trial name
- NCT00291135
- Testing
- letrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Carol Fabian, MD
Tobacco Smoking
Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)
This study shall determine whether or not proactive telephone support for smoking cessation delivered to quitline callers is more effective than standard 'reactive' provision and whether or not the offer of a voucher for a cost…
- Trial name
- PORTSSS (NCT00775944)
- Testing
- Proactive telephone support, Reactive (standard) telephone support, Offer of voucher for cost-free Nicotine Replacement Therapy
- Where
- United Kingdom
- Volunteers
- 2,591 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Mild Cognitive Impairment, Alzheimer's Disease
Hormone and Information Processing Study
The purpose of this study is to examine the effects of testosterone (T) replacement on changes in thinking and memory, as well as mood in older men with mild cognitive impairment (MCI) and low T levels.
- Trial name
- HIP (NCT00539305)
- Testing
- testosterone gel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency
This was the first clinical study of SBC-102 (sebelipase alfa) for the treatment of Lysosomal Acid Lipase (LAL) Deficiency. It was an open-label dose escalation study in adult participants with liver dysfunction due to LAL…
- Conditions
- Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
- Trial name
- NCT01307098
- Testing
- Sebelipase alfa 0.35 mg/kg, Sebelipase alfa 1 mg/kg, Sebelipase alfa 3 mg/kg
- Where
- 7 sites in United States, Czechia and 2 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.